Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19

NCT04406233 | Unknown

• 1 other identifier: 31303720.7.0000.0068
• Study Type: observational
• Target: 176
• Locations: 1 country
• Sites: 1

Brief Summary

The severe acute respiratory syndrome induced by the new coronavirus (SARS-CoV-2) has been declared a worldwide pandemic. Identifying common characteristics of the disease is crucial to promote a better prognosis for patients and to reduce the occurrence of medical complications, the time to medical discharge and mortality rates. Muscle mass and strength are recognized predictive measures of medical complications and mortality in different populations, but it is still unclear whether these also applies to patients with SARS-CoV-2. Therefore, this study will investigate whether muscle mass and/or muscle strength are predictors of the time until medical discharge of patients hospitalized with SARS-CoV-2. Our working hypothesis is that muscle mass and/or muscle strength are predictive measurements of the time until medical discharge of patients hospitalized with SARS-CoV-2

Conditions

SARS-CoV 2

Outcome Measures

Primary Outcomes (1)

• Time to medical discharge

  Length (in days) of the time hospitalization until medical discharge

  through the hospitalization period, an average of 15 days

Secondary Outcomes (2)

• All-cause mortality

  through the hospitalization period, an average of 15 days, 60, 180 and 360 days after medical discharge

• Hospital readmission

  60, 180 and 360 days after medical discharge

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with SARS-CoV-2

You may qualify if:

• Years and older ;
• hospital stay less than 48 hours;
• length of hospital stay to 48 hours no requiring invasive mechanical ventilation;

You may not qualify if:

• cancer in the last 5 years;
• delirium;
• cognitive deficit that impossibility the patient to read and sign the informed consent form;
• neurological disease;
• degenerative muscular disease.

Sponsors & Collaborators

• University of Sao Paulo: lead

Study Sites (1)

Univsersity of Sao Paulo

São Paulo, 05508-030, Brazil

RECRUITING

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Phd

Study Record Dates

• First Submitted: May 23, 2020
• First Posted: May 28, 2020
• Study Start: May 23, 2020
• Primary Completion: May 23, 2022
• Study Completion: May 23, 2022
• Last Updated: May 28, 2020

Record last verified: 2020-05

Locations

BR (1)